| Name | Title | Contact Details |
|---|
Northwest Parkinson's Foundation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Serving markets in the US and Canada, Vision Group Holdings oversees and manages the leading LASIK and laser eye surgery providers in North America.
A10 Clinical Solutions is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RecordFlow is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.